Tuesday, April 20, 2021 |

Emergent BioSolutions calls J&J vaccine manufacturing error at Baltimore facility ‘disappointing’

April 2, 2021

Emergent BioSolutions Inc. (NYSE: EBS) issued a statement Thursday following the news its Baltimore manufacturing facility was responsible for contaminating up to 15 million doses of Johnson & Johnson’s Covid-19 vaccine, which the Gaithersburg company is helping to produce. “At Emergent, safety and quality are our top priorities,” the company said in its statement. “Our Bayview facility has been designed and validated to meet all current Good Manufacturing Practices. In addition, there are rigorous quality checks throughout our vaccine manufacturing processes, and through these checks a single batch of drug substance was identified that did not meet specifications and our rigorous quality standards. We isolated this batch and it will be disposed of properly.”

Article Source: Baltimore Business Journal

The Morning Rundown

We’re staying up to the minute on the issues shaping the future. Join us on the newsletter of choice for Maryland politicos and business leaders. It’s always free to join and never a hassle to leave. See you on the inside.